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In vitro and in vivo activity of amoxicillin and penicillin G alone or combined with a penicil-
linase inhibitor (clavulanate) were tested against five isogenic pairs of methicillin-resistant Staph-
ylococcus aureus (MRSA) producing or not producing penicillinase. Loss of the penicillinase
plasmid caused an eight times or greater reduction in the MICs of amoxicillin and penicillin
G (from ~64 to 8 J-tg/ml), but not of the penicillinase-resistant drugs methicillin and cloxacillin
(~64 J-tg/ml). This difference in antibacterial effectiveness correlated with a more than 10 times
greater penicillin-binding protein 2a affinity of amoxicillin and penicillin G than of methicillin
and a ~90% successful amoxicillin treatment of experimental endocarditis due to penicillinase-
negative MRSA compared with cloxacillin, which was totally ineffective (P < .001).Amoxicillin
was also effective against penicillinase-producing parent MRSA, provided it was combined with
clavulanate. Penicillinase-sensitive [3-lactamantibiotics plus penicillinase inhibitors might offer
a rational alternative treatment for MRSA infections.
Mostclinical isolatesof methicillin-resistant Staphylococ-
cus aureus (MRSA) carry two distinct antibiotic resistance
mechanisms: Theyproducepenicillinase, whichresults in the
elevation of the MICvalues ofpenicillinase sensitive ~-lactam
antibiotics, and theycarry "intrinsic resistance;' an as yet in-
completely understood mechanism associated withtheproduc-
tion of a new penicillin-binding protein (PBP 2' or 2a) with
low ~-lactam affinity [1]. In the absence of penicillinase
production, intrinsic resistancealone can provideMRSA re-
sistance (i.e., increased MICvalues) to mosttypesof ~-lactam
antibiotics, whetheror not the latter can resisthydrolysis (in-
activation) by bacterial penicillinases (for review, see [2]).
Despite the combinationof penicillinasesecretionand in-
trinsic resistance, it has been possible to cure experimental
endocarditisdue to MRSAby treatment with combinations
of penicillinase-sensitive ~-lactam antibiotics andpenicillinase
inhibitors [3, 4]. One straightforward interpretationof these
observations wasthatinactivation of thebacterial penicillinase
bypenicillinase inhibitors protected thepenicillinase-sensitive
drugsfromenzymatic degradation, thusallowing themto over-
comeintrinsicresistance. However, experimental demonstra-
tion of these properties has been lacking. The successof the
combinationtherapycould havebeen causedbya synergistic
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antibacterial effect of the twoagents; both are knownto have
antimicrobial activities [5].
In thepresentexperiments weinvestigated themechanism(s)
of actionof combinations of penicillinase-sensitive ~-lactam
antibiotics andpenicillinase inhibitors byusingisogenic pairs
of MRSA that did or did not produce penicillinase.
Materials and Methods
Microorganisms and growth conditions. The principal charac-
teristics of the sevenstaphylococcal isolates used are summarized
in tables 1 and 2. MRSA1-4 were selectedfor temperature-induced
loss of penicillinaseplasmids (see below) from 30 clinical isolates
of MRSA (describedin [4])originatingfrom patientsin severalEu-
ropeancountries. MRSA5 wasa penicillinase-negative clinical iso-
late obtained from the Division of Microbiological Reagent and
Quality Control, London. Strains RN2677 and COL (providedby
A. Tomasz, Rockefeller University) were two laboratory strains of
S. aureus respectively sensitive and homogeneously resistant to
methicillin [6], which we used as reference strains.
Unless otherwise stated, isolates were grown at 35°C in tryptic
soybroth (TSB; DifcoLaboratories, Detroit) or on tryptic soyagar
(TSA; Difco) supplemented with 4% NaC!. Stocks were kept at
-70°C in TSB supplemented with 10% glycerol.
Antibiotics. PenicillinG wasobtained from Hoechst (Frankfurt
am Main, Germany);cloxacillin, amoxicillin,andclavulanatefrom
BeechamResearchLaboratories (BrockhamPark, UK); vancomy-
cin from Eli Lilly (Indianapolis); and [3H]penicillin (65.2 mCi/mg)
from Merck Sharp & Dohme (Rahway, NJ).
Cure ofpenicillinase production. Penicillinase-producing and
cadmium-resistantisolates of MRSAwere tested for temperature-
inducedlossofthennosensitive plasmid[7].Bacterialculturesgrown
to exponentialphase at 35°C were transferred (100 Jl.l) into tubes
containing 10 ml of fresh prewarmedTSB and grown overnightat
43°C. The cultures were then reinoculated (100 Jl.1) in fresh TSB
for a second and a third passage at 43°C. Since plasmids confer-
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Table 1. Epidemiologic characteristics of five clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA).
Disk susceptibility test
Clinda- Erythro- Chloram- Penicillinase
MRSA isolate, source, year Disease Gentamicin mycin mycin phenicol Lysotype plasmid (kb)
1, Paris, 1984 Endocarditis R R R S Nontypable 24
2, Vevey, Switzerland, 1985 Wound infection S R R R Nontypable 15
3, Lausanne, Switzerland, 1981 Endocarditis R R R R 84 ND
4, Paris, 1983 Endocarditis R R R S Nontypable ND
5, London, 1985 ND S S R S Nontypable ND
NOTE. R = resistant, S = sensitive, ND = not determined.
Table 2. Antibiotic susceptibilities of methicillin-resistant Staphylococcus aureus isolates thatpro-
duce (+) or do not produce (-) penicillinase.
Isolate
MRSA
RN2677 COL 2 3 4 5
Parent's phenotype
Penicillinase production + + + +
Expression of methicillin-R S Homo Het Het Het Het Het
MIC (ug/rnl)"
Methicillin
+ >64 >64 >64 64
>128 32 >64 128 64 64
Cloxacillin
+ 32 32 64 64
0.25 >128 32 32 128 64 32
Penicillin
+ 128 128 128 >128
0.004 8 4 8 8 4 16
Amoxicillin
+ 128 128 >128 >128
0.125 16 8 8 8 8 16
Amoxicillin and clavulanate
+ 16 8 16 8
0.125 16 8 8 8 8 16
Clavulanate
+ 128 128 128 >128
2 >128 128 128 >128 >128 128
Vancomycin
+ 1 1 2
2 2 2 2 2
NOTE. Homo and Het, homogeneously and heterogeneously resistant (R) to methicillin. S = susceptible.
* MIC values were determined after 24 h of incubation at 35°C.
ring resistanceto heavy metalsalsooftenbear penicillinase-encod-
ing genes [8], the cultures were first screened for the presence of
clones thathadlostcadmium resistance. Dilutions ofthecultures were
platedon plain TSA to a total of 2-5 X 102 cfu/plate, grown over-
night at 43°C, and replica plated on TSA containing 10-4 mol of
cadmium. The colonies able to grow on plain but not cad-
mium-containing TSA were isolated and tested for penicillinase
productionby a nitrocefin [9] and a starch-Lugol method. In some
ofthecadmium-sensitive andpenicillinase-negative derivatives, plas-
mid loss wasfurther visualized by DNAgel electrophoresis as de-
scribed [10]. Identity of biochemical reactionpatternsbetweenthe
penicillinase-producingparentisolates andtheirpenicillinase-negative
derivatives wasalsocontrolled (APIStaph.; APISystem, Montalieu
Vercieu, France).
Antibiotic susceptibility. MICsof several antibiotics weredeter-
minedbya standard macrobroth method [11] in Mueller-Hinton broth
(Difco) supplemented withcalcium and 2%NaCl, as recommended
forsusceptibility testing ofMRSA [12]. MICofantibiotics wasdefined
as the lowest drug concentration (in micrograms per milliliter) in-
hibitingvisiblebacterial growth after 24 h of incubation at 35°C.
For MIC determinations of the combination of amoxicillin and
clavulanate, the drugs were used in a ratio of 2:1 (wt/wt). Disk
diffusion tests were done by a standard method [13].
Population analysis profile. The phenotypic expression of
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methicillin resistance invitrovaries greatly fromstrainto strain[14].
Mostisolates exhibit a so-called "heterogeneous" resistance, inwhich
only a few cells in a culture (10-4-10-8 cfu/ml) have high MIC
values (>500 JLg of methicillin/ml), whereas in less frequent
"homogeneously" resistantisolates, all the cells in a cultureexpress
highresistance levels [6, 14].Thephenotypic expression ofJ3-lactam
resistance wastestedas follows. Culturesof MRSA isolates grown
at 35°Cto lateexponential phasewereseriallydiluted anddispersed
on TSA platescontaining 4% NaCl and twofold serial dilutions of
antibiotic. Large(>108 cfu)and smaller(1()6, 104, and H)2cfu)bac-
terial inoculawereplated. The numbers of colonies growing on the
antibiotic-containing plates were determined after 48 h of incuba-
tion at 35°C. Population analysis profilecurves weregeneratedby
plotting the numbers of colony-forming units growing on the plates
against the concentrations of antibiotic in the plates (see figure 1).
Titrations ofPBP2a. The presenceof PBP 2a wasdetermined
in membrane fractions of MRSA lysatesas previously described [6,
15].Briefly, 45-JLl portionsof membranesuspensions containing 4
mg/ml protein were incubated for 10 min at 37°C with 5 JLl of a
1:10 (wt/wt) solutionof PH]penicillin and cold penicillin to a final
concentration of 1.8 JLg of [3H]penicillin/ml of membrane suspen-
sion.Thereactionwasstoppedbyadditionofan excess ofcoldpen-
icillin, andthemembranes weredissolved bythedetergent sarkosyl.
The membrane proteins were separated by SDS-PAGE and the
[3H]penicillin-labeled PBPs were visualized by fluorography.
Thebindingaffinities of penicillin, amoxicillin, clavulanate, and
methicillin for PBP2a weredetermined by measuring their ability
to competefor the bindingof pH]penicillin to PBPs. Aliquots of
membrane suspensions were distributed into series of tubes con-
taining twofold serial dilutions of the competitorand incubated at
37°C for 10 min before pH]penicillinwas added. The tubes were
incubated at 37°C for another 10min and processed as described.
Intensities of the PBP2a bandson the fluorographs weremeasured
by scanning densitometry.
Production ofendocarditis in rats. Sterileaorticvegetations were
produced in female Wistarrats (weight 180-200 g) bymodification
of a describedmethod[16]. Briefly, a polyethylene catheter (PPI0;
Portex,Hythe,UK)wasinsertedacrosstheaorticvalvevia theright
carotidartery and securedwith a silk ligature. At 12 h after cathe-
terization, the rats were inoculated in a tail vein with 0.5 ml of sa-
line containing lOS cfu of the test organism (see Results).
Treatmentprotocolandevaluation ofinfection. Antibiotic treat-
ment was started 12 h after intravenous (iv) inoculation, a time at
whichthe bacterial density on the valves was 107-1OS cfu/gof vege-
tation, as shown byuntreatedcontrolanimals. Groupsof rats were
treated for 3 days with subcutaneous (sc) injections of one of the
following regimens: cloxacillin (200 mg/kgevery5 h); amoxicillin
(125 mg/kgevery5 h); amoxicillin and clavulanate (ratio, 5:1 [i.e.,
125mg/kgof amoxicillin and 25 mg/kgof clavulanate] every5 h);
or vancomycin (30mg/kg every 6 h). In someexperiments withamox-
Figure 1. Population analysis profiles of
penicillinase-producing clinical methicillin-
resistantStaphylococcus aureus isolates 1and
2 (A, C), their penicillinase-negative deriva-
tives (B, D), and the homogeneously
methicillin-resistant reference strainCOL(E).
Bacteria (>108 cfu/plate) wereplatedon tryp-
tic soyagarsupplemented with4% NaCIand
twofold serial dilutions of either methicillin
( ), amoxicillin (0--0), or amox-
icillinandclavulanate (0- - -0). Clavulanate
wasusedat a fixed concentration of32 JLg/ml.
The numbers of colonies growing on the
antibiotic-containing plates were determined
after 48 h of incubation at 35°C.
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icillinandclavulanate theproportionofclavulanate in the antibiotic
combination wasincreased either bydoubling the numberof injec-
tionsofclavulanate (to be referredto as the 5:2 ratio)or by increas-
ingboththenumber of injections andthedosage ofthedrugto obtain
a final drug ratio of 5:5 (wt/wt).
Treated rats werekilledafter 3 days of therapy, 12h after the last
dose of antibiotic, whenno antibiotic activitywasdetectablein the
blood. Aortic vegetations were excised, weighed, homogenized in
1 ml of saline, seriallydiluted, and plated. Colonies were counted
after 48 h of incubation at 35°C and the resultsexpressed in 10glO
colony-forming unitsper gramofvegetation. Thedilution technique
permitted the detection of ~102 cfu/g of vegetation. "Successful
treatment" wasdefined as rats with no detectablebacteria on their
aortic valves «102 cfu/g of vegetation). Bacteria recovered from
valves oftreatment failures wereeitherdirectly plated ontoantibiotic-
containing platesor stored at -70°C for subsequent MIC determi-
nation.
Antibiotic serum levels. Serumconcentrations ofantibiotics were
determined by an agar-diffusion technique [17] usingBacillus sub-
tilis (subtilissporesuspension; Difco) for cloxacillin andvancomy-
cin, Sarcina lutea ATCC 9341 for amoxicillin, and Klebsiella
pneumoniae ATCC 10031 plus24 JLg ofpenicillinlml forclavulanate.
Serum sampleswere taken from normal rats at varioustimesafter
one sc injectionof antibiotic.
Statistical analysis. The two-tailed Fisher'sexacttest wasused
to compare treatment groups.
Results
Cure of Penicillinase Production and
Susceptibility of Organisms
Among 30cadmium-resistant andpenicillinase-producing
clinical isolates of MRSA that were tested for temperature-
induced lossof plasmid, 4 yieldedcadmium-sensitive clones
after overnight growth at 43°C. All of thesecloneshad con-
comitantly lost their ability to producepenicillinase. In two
pairs of penicillinase-producing parent isolates and their
penicillinase-negative derivatives that werefurther analyzed
(MRSAI and 2, see tables 1 and 2), the simultaneous loss
of thecadmium andpenicillinase markers correlated withthe
loss of a unique plasmid from the bacterium, as visualized
by DNA gel electrophoresis. This suggests that the loss of
penicillinase production had resulted from elimination of a
thermosensitive plasmid bearingboththe cadmium resistance
and the penicillinase genetic determinants.
Table 1summarizes epidemiologic characteristics ofthefive
clinical isolates of MRSA used in this study. It appears that
MRSAl, 2, 3, and 5 likely represented different strains of
MRSA. In contrast, MRSAI and 4 could not be clearly
differentiated on the basis of table 1. However, since these
bacteriawere isolated at different times fromtwo individual
patients with endocarditis, theymayalsobe different strains
ofMRSA.
Table 2 summarizes the susceptibilities to several (3-lactam
antibiotics and to vancomycin of the four penicillinase-
producing parent isolates and their penicillinase-negative
derivatives (MRSAI-4), the penicillinase-negative isolate
MRSA5, andthe twopenicillinase-negative reference strains
RN2677 (methicillin-susceptible) and COL (homogeneously
methicillin-resistant). Elimination of the penicillinase activ-
ityof thebacteria, eitherbylossofthepenicillinase-encoding
plasmidor byinhibition of the penicillinase with the inhibi-
tor clavulanate, resulted in a dramatic decrease in the MIC
values of both penicillin and amoxicillin (from ~128 to 8
/tg/ml). In contrast, the MIC values of methicillin, cloxacil-
lin, or clavulanate were not altered by loss of penicillinase
production of the bacteria.
In Vitro Expression of Intrinsic Resistance in Penicillinase-
Producing or Non-Penicillinase-Producing MRSA
The in vitro resistancephenotypes of the MRSA isolates
described in table2 weredetermined bytheirpopulation anal-
ysisprofiles on agarplatescontaining increasing concentra-
tions of either methicillin, penicillin G, amoxicillin, or
amoxicillin andclavulanate. Allwereheterogeneously resis-
tant to methicillin, except for the reference strains RN2677
andCOL, whichwererespectively sensitive andhomogene-
ously resistant to this drug (table2). Figure 1 shows repre-
sentative curves ofpopulation analysis profiles fortwo isogenic
pairs of penicillinase-producing or nonproducing MRSA
(MRSAI and 2) and for the homogeneously resistant strain
COL. Loss of penicillinase production did not alter the ex-
pression ofmethicillin resistance in eitherMRSAI or 2 (figure
1,A-D). Incontrast,elimination of the penicillinase activity
by loss of the penicillinase gene of the bacterium or by ad-
dition of the penicillinase inhibitor clavulanate increased
the sensitivity of both isolates to amoxicillin by a factor of
~15. Similar results were also obtained with the isogenic
penicillinase-producing or non-penicillinase-producing iso-
lates MRSA3 and 4, with the penicillinase-negative clinical
isolate MRSA5, and when penicillin was used in place of
amoxicillin (datanotshown; tables 1and2 show characteris-
tics of the isolates). In eachof the above isolates, thepattern
of population analysis profile on amoxicillin- (or penicillin
G-) containing platesparalleledtheir typicalheterogeneous
patternon methicillin (figure 1, A-D). The results obtained
withthehomogeneously resistantcontrolstrainCOL (figure
IE) also paralleled the observations describedabove in that
strainCOLwas~15 timesmoresensitive to amoxicillin than
to methicillin and its population analysis profile washomo-
geneous on bothamoxicillin andmethicillin-eontaining plates.
Thus,whencompared withmethicillin, amoxicillin (orpeni-
cillin G) resultedin vitro in a major shift of the population
analysis profile curve toward a decreased level of antibiotic
resistance, provided that thepenicillinase activity of thebac-
teriawas alsoeliminated. In suchconditions, noneofthe iso-
lates testedwasable to grow on agar plates containing >50
/tgofamoxicillin (orpenicillin G)/mlevenwheninocula were
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>108/cfu/plate. In contrast, all isolates grew on >500 p.g/ml
methicillin.
Antibiotic Treatment of Experimental Endocarditis Due
to Penicillinase-Producing or Non-Penicillinase-
Producing MRSA.
We further investigated the ability of amoxicillin to over-
come intrinsic resistance of MRSA in vivo using a rat model
of aortic endocarditis (see Materials and Methods). Animals
were infected with the two isogenic pairs of penicillinase-
producing or nonproducing MRSAI and 2, the penicillinase-
negative isolate MRSA5, and the penicillinase-negative and
homogeneously resistant reference strain COL (table 2). Each
isolate was equally capable of inducing endocarditis in the
rats as determined by the minimum size of bacterial inocula
that produced endocarditis in 90% of the animals: rvlQ4-cfu
(data not shown).
Antibiotic regimen. The antibiotic regimens are described
in Materials and Methods. Vancomycinwas used as reference
for treatment efficacy, because it is the antibiotic recommended
for treatment of severe MRSA infections in humans (see [2]).
Cloxacillin was used instead of methicillin in in vivo experi-
ments, because the latter antistaphylococcal drug is rarely used
in clinical medicine. Moreover, based on in vitro susceptibil-
ity tests (table 2), cloxacillin was expected to be equal or
superior to methicillin for treatment of MRSA infections. The
therapeutic regimens were adjusted to mimic in rats the se-
rum levels of antibiotics in humans after therapeutic doses
of the drugs. Table 3 compares the serum levels and half-lives
of the antibiotics after one therapeutic dose in rats to those
in humans reported by others [18-21]. The kinetics of clox-
acillin and amoxicillin were comparable between rats and hu-
mans. In contrast, the serum half-lives of both clavulanate
and vancomycin were strikingly shorter in rats than in hu-
mans (i.e., respectively, 20 vs. 60 min for clavulanate and
1.5 vs. 6 h for vancomycin). Therefore, in some therapeutic
experiments the dosage of clavulanate given to the rats was
increased (see below), and vancomycin was administered to
the rats twice as often as recommended in humans (i.e., ev-
ery 6 h instead of every 12 h).
Treatment ofendocarditis due to heterogeneously resistant
MRSA. Figure 2 shows that cloxacillin failed to lower the
bacterial densities on the valves of rats infected with either
isogenic pair of penicillinase-producing or nonproducing
MRSAI and 2 (mean bacterial densities, ~108 cfu/g of vege-
tation). In striking contrast, amoxicillin alone successfully
treated (i.e., <102 cfu/g of vegetations) 100% of the infec-
tions due to either penicillinase-negative derivative but, as
expected, was ineffectivein infections due to the penicillinase-
producing parent isolates.
The combination of amoxicillin and clavulanate given in
the "standard" ratio of 5:1 (the ratio used in adult humans)
also successfully treated most of the infections due to
penicillinase-negative bacteria (figure 2). However, this com-
bination was effective in only 40 % of infections caused by
the penicillinase-producingparent MRSAI and in 70 % of those
due to MRSA2. The treatment failures in this group were not
due to selection for mutants with increased antibiotic resis-
tance, as bacteria recovered from the valves and directly plated
on antibiotic-containing agar retained the MIC values of the
parent (data not shown).
The relative ineffectiveness of the "standard" 5:1 regimen
of amoxicillin and clavulanate could be overcome by increas-
ing the proportion of clavulanate in the antibiotic combina-
tion. Because the serum half-life of clavulanate is rather short
in rats (table 3), the bioavailability of the drug given 5:1 might
have been too low to counteract the production of bacterial
penicillinase in situ. Figure 3 illustrates an experiment in
which the ratio of amoxicillin to clavulanate was increased
from 5:1 to 5:2 and to 5:5. While the 5:1 ratio successfully
treated only 30 % of the infected animals, the rate of success
increased respectively to 70 % and 93 % with drug ratios of
5:2 and 5:5.
In therapeutic experiments with the penicillinase-negative
clinical isolate MRSA5, amoxicillin alone successfully treated
endocarditis in 60% (8 of 12) of the rats, whereas none (0
of 8) responded to cloxacillin treatment (P < .01 compared
with amoxicillin treatment) and only 44% (4 of 9) were suc-
cessfully treated by the reference treatment with vancomycin
(P < .05 compared with cloxacillin treatment).
Treatment ofendocarditis due to the homogeneously resis-
Table 3. Comparisons of peak serum levels and serum half-lives of antibiotics after one thera-
peutic dose in rats and for humans.
Rats (n = 3-5) Humans
Dose Peak Half-life Peak Half-life
Antibiotic (mg/kg) (ug/ml)> (h) (ug/ml)" (h) Reference
Cloxacillin 200 118 ± 20 0.6 70-100 0.5 [18, 19]
Amoxicillin 125 89 ± 24 0.7 100-120 1 [19, 20]
Clavulanate 25 21 ± 3 0.3 15-20 1 [19, 20]
Vancomycin 30 39 ± 12 1.5 20-50 6 [21]
* 15-30 min after parenteral administration.
tantstrain COL. The clinicalisolates of MRSA usedin the
rat experiments wereofthe heterogeneously resistantpheno-
type (table 2). Thus, it is possible that only a few bacteria
on the infected valve expressed high resistance levels at the
beginning ofantibiotic treatment. Sucha phenomenon might
overemphasize the actual therapeutic efficacy of amoxicillin
against intrinsically resistant MRSA [22]. To address this
question, weperformed controlexperiments using the homo-
geneously resistantstrainCOL to infectthe rats. In suchex-
periments, all bacteria on the infected valves were expected
to express highlevels of t1-lactam resistance at the beginning
of antibiotherapy. Figure 4 shows that amoxicillin success-
fully treated 100% of endocarditis cases due to COL (17 of
17),whereascloxacillin was totally ineffective andvancomy-
cin treatment was successful in only 44% of the infected
animals (7 of 16; P < .05compared with amoxicillin treat-
ment). These results clearlyconfirmthe abilityof amoxicil-
lin to overcome intrinsic resistance of MRSA in vivo. They
also confirm the observation that amoxicillin is equal or su-
perior to vancomycin for the treatment of MRSA endocardi-
tis in rats, when the penicillinase activity of the strain is
eliminated.
Antibiotic Affinity for PBP 2a
Since intrinsic resistance of MRSA is associated with the
production ofa new PBP(PBP2a)withlowt1-lactam affinity,
wequestioned whetherthe successful antiintrinsic resistance
effect of amoxicillin and penicillin might correlate with a
greateraffinity for PBP2a compared withthatof methicillin
(which doesnotovercome intrinsic resistance) [15, 23]. Thus,
we compared the PBP 2a affinity of amoxicillin, penicillin
G, andclavulanate withthatofmethicillin bymeasuring their
ability to compete against the binding of PH]penicillin to the
PBPs. Series of membrane samples were processed strictly
in parallel and run on the same gel. Figure 5 illustrates an
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Table 4. Relative affinities (in arbitrary units) of ~-lactam anti-
biotics for penicillin-binding protein (PBP) 2a.
Isolate
NOTE. One unit was defined as the concentration of methicillin necessary to sat-
urate 50% ofPBP 2a. Data were extrapolated from affinity plots as shown in figure 5.
erence strainRN2677. Therefore, the anti-MRSA activityof
amoxicillin and penicillin appeared to correlate rather spe-
cifically with their binding affinity for PBP 2a.
COL
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Figure 4. Antibiotic treatment of experimental endocarditis due
to homogeneously methicillin-resistant reference strain COL. De-
tails are as in figure 2.
Figure 3. Treatment of experimental endocarditis with amoxicil-
lin combined with increasing concentrations of penicillinase inhibi-
tor clavulanate. Infecting organism was penicillinase-producing
clinical isolate, methicillin-resistant Staphylococcus aureus1.Treat-
ment groups 5:1, 5:2, and 5:5 are respective ratios of amoxicillin
to clavulanate, 125:25, 125:50, and 125:125 mg/kg. Details are as
in figure 2.
experiment withstrainCOL. It shows that the affinity ofboth
amoxicillin andpenicillin G for PBP2a (asexpressed bytheir
abilityto saturate50% of the PBP) was more than 10 times
greater than that of methicillin. In contrast, clavulanate did
notbindto PBP2amorethanmethicillin. Comparable results
were obtained with the penicillinase-negative derivative of
MRSAI (table 4).
Longerexposure ofthe autoradiographs showed thatamox-
icillinand penicillinalso had higher affinities then methicil-
lin for PBP2 but apparently not for the other staphylococcal
PBPs(figure 5). Similarobservations weremade for the ref-
Our results underline the importance of the ubiquitous
secretionof penicillinase in the problem(s) of "anti-MRSA"
chemotherapy. Most MRSA isolates contain two distinct
mechanisms of 13-lactam resistance, and the contributions of
these to the elevated MIC values may be clearly separable
both in vitro and in vivoby the experiments describedhere.
The contribution ofpenicillinase productionto the MIC was
identified by the use of penicillinase-sensitive and -resistant
antibiotics alone or in combination with clavulanate against
isogenic pairs of MRSA that did or did not producepenicil-
linase. Whilebacterial growth ofpenicillinase-negative MRSA
wascompletely inhibited by relatively lowconcentrations of
amoxicillin or penicillin G, it was hardly affected by either
methicillin or clavulanate. However, combination withclavu-
lanate was absolutely required for amoxicillin to overcome
resistance of penicillinase-producing isolates. Therefore,
as hasbeenpreviously suggested, theroleofclavulanate in the
antibiotic regimen was restricted to theprotection ofthepeni-
cillinase-sensitive 13-lactam from enzymatic degradation,
thus allowing the latter compound to overcome intrinsic re-
sistance. Themechanism of irreversible inhibition ofpenicil-
linase by clavulanate has been described elsewhere [5].
Theantiintrinsic resistance activity ofamoxicillin andpen-
icillin G correlatedwith more than 10 times greater affinity
for PBP2a compared with that of methicillin or clavulanate
(which do not overcome intrinsic resistance). PBPs are
membrane-bound enzymes that mediate several steps in the
processof cell wallsynthesis and are inactivated by forming
stable acyl-enzyme intermediates with 13-lactam antibiotics
(for review see [24]). It has been suggested that the 10w-l3-
lactam-affinity PBP2aofMRSA mightsubstitute forthefunc-
tion of "normal" PBPs when the latter are inactivated by 13-
lactam antibiotics [25]. If so, then inhibition of PBP2a may
be a keymechanism of MRSA inhibitionby amoxicillin and
penicillin G. A clue for the specific binding of amoxicillin
and penicillin G to PBP 2a is that these drugs did not bind
to a muchlargerextent thanmethicillin or clavulanate to other
staphylococcal PBPs (except for PBP 2). Moreover, amox-
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Figure 5. Penicillin-binding protein(PBP)2a affinity of antibiotics. Membrane sampleswereprocessed in parallel and run on samegel.
A, Fluorographs showing (left) high-molecular-weight PBPsofmethicillin-sensitive reference strainRN2677 andofbothmethicillin-resistant
Staphylococcus aureus 1 and COL (PBP 1, PBP2, PBP 2a, PBP3), and (right)PBP2a-bindingaffinities of amoxicillin versusmethicillin
for the homogeneously resistant reference strain COL. Albumin (Alb) and concentrations of competitordrug are indicated. B-D, Affinity
plotscomparing PBP2a affinity of methicillin to amoxicillin (B), penicillin(C), and calvulanate (D). Dashedlines indicateconcentrations
of drugs resulting in 50% saturation of PBP 2a.
icillinandpenicillin did notalter the shapeof the population
analysis profile of the isolates, which is another important
characteristic of [3-lactarn resistance of MRSA. It has been
shown thatphenotypic expression ofmethicillin resistance is
regulated byauxiliary genes on thebacterial chromosome and
does not correlate with the amount of PBP 2a produced by
the bacterium[6,26]. The factthat arnoxicillin or penicillin
G did notqualitatively alter the expression of theseauxiliary
genesfurther restrictsthe likelybacterialtargets of these{3-
lactarnantibiotics to PBP2a. This is also in accordwiththe
experimental evidence fortheessential nature ofanintactPBP
2a genefor the high{3-lactam MICvalues of MRSA [6, 27].
The reason for the relatively good PBP 2a affinity of the
penicillinase-sensitive {3-lactam antibiotics amoxicillin and
penicillin G is a matterof speculation. BothPBPsandactive-
site-serine penicillinases ofknown structure belong to a com-
monfamily ofpenicillin-recognizing enzymes [28]. Possibly
{3-lactam antibiotics with high affinity for certain PBPs are
also goodsubstrates for degradation by penicillinases. Thus
other penicillinase-sensitive {3-lactarn antibiotics may have
good"anti-MRSA" activity as well. As our understanding of
the interactions between [3-lactam molecules and penicillin-
binding enzymes progresses, molecules may be designed that
simultaneously bind to and inactivate both PBP2a and bac-
terialpenicillinases. Indeed, thereareprecedents forsuch"bi-
functional" {3-lactam antibiotics that inhibit both PBPs and
penicillinases [29].
It is noteworthy that phenotypic expression of intrinsic re-
sistance(i.e., whether the strainsexpress the heterogeneous
or homogeneous type of resistance) may influence the out-
comeof[3-lactam treatment ofMRSA infections, because the
success ofantibiotherapy may depend onthenumber ofhighly
resistantbacteriapresentat the infection siteat thebeginning
oftreatment [22]. In thepresent experiments, amoxicillin treat-
mentsuccessfully curedexperimental endocarditis duetoboth
heterogeneously and homogeneously resistant MRSA (pro-
videdthat the bacterialpenicillinase activitywasalso elimi-
nated), thus demonstrating its efficacy against both typesof
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resistant bacteria. When clavulanate was used to inhibit
penicillinase, the successful therapeuticoutcomeappearedto
be dose-dependent (see figure 3). Althoughthis wasobviously
due to the shortserumhalf-life ofclavulanate in rats, it stresses
theriskoftreatment failure ofarnoxicillin against penicillinase-
producing MRSA when the concentration of clavulanate at
the infection site is inadequate.
Despite the fact that the therapeutic regimens used in rats
yieldedrather highpeak serum levels of antibiotics, theywere
consistentwith thoseobtained inhumansduringiv treatment.
Therefore, provided that adequate concentrations of both
amoxicillinand clavulanatecan be obtained at the infection
site, the combinationof these antibiotics mightbe successful
in the treatment of MRSA infections in humans as well. In
this regard, it should be remembered that the therapeutic
efficacy of amoxicillinand clavulanate in animals was either
equalor superior to thatof vancomycin, the treatmentrecom-
mended for severe MRSA infections in humans [2].
The presentexperimentsused at least fivedifferentisolates
of MRSA (MRSAl, 2,3,5 and COL; tables 1 and 2), and
in each case the in vivo therapeutic outcomeof experimental
endocarditis correlated with the in vitro antibiotic suscepti-
bilityof the infectingorganism. Previous reports suggestthat
this correlation may also be true for other clinical isolates
of MRSA [3, 4].
In conclusion, the results underline the important contri-
butions of both the secretion of penicillinase and the PBP
2a-related mechanism of resistance to the poor susceptibil-
ity of MRSAisolates to J3-lactarn antibiotics. Taking all fac-
tors together, the primary problem for the effective J3-lactarn
therapy of MRSAinfectionsappears to be the production of
penicillinasebymost clinical isolatesof MRSA. Appropriate
"silencing" of this enzyme (by inhibitors) allowsan effective
inhibition of these strains, both in vitro an in vivo, by such
familiar antibacterial agents as arnoxicillin and penicillin G.
Theseagents inhibitgrowthof MRSA at concentrations 10-15
times lowerthan thoseof the penicillinase-resistantt3-lactarn
methicillinand cloxacillin, and the differentialPBP2a affini-
tiesdeterminedin our studies providea mechanisticexplana-
tion. Since combinationsof penicillinase-sensitive t3-lactarn
antibiotics plus penicillinase inhibitors may offer a rational
alternativetreatment for MRSAinfections, further investiga-
tions are warranted to determine if such regimensmayeffec-
tively treat MRSA infections in humans.
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